Metraipolis › archive › dc_fc2fd758ad7c
Why does LDL-C follow a different paradigm from other endocrine-metabolic diseases in cardiovascular prevention? — Europe PMC PMID:42125229
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/42125229
- DOI
- 10.3389/fendo.2026.1813342
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-03T03:15:54.709Z
- SHA-256 of the archived text
c59ed9cb37a1198ba18c8942d14bb4256a460d2cfd4f9ffbaa84b4a84e3d77df- Stable URL of this page
https://metraipolis.com/documento/dc_fc2fd758ad7c
How to cite
Why does LDL-C follow a different paradigm from other endocrine-metabolic diseases in cardiovascular prevention? — Europe PMC PMID:42125229 — Europe PMC (en), https://europepmc.org/article/MED/42125229 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_fc2fd758ad7c (Metraipolis archive dc_fc2fd758ad7c, sha256 c59ed9cb37a1198ba18c8942d14bb4256a460d2cfd4f9ffbaa84b4a84e3d77df)
BibTeX
@misc{dcfc2fd758ad7c,
title = {Why does LDL-C follow a different paradigm from other endocrine-metabolic diseases in cardiovascular prevention? — Europe PMC PMID:42125229},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/42125229},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_fc2fd758ad7c; sha256 c59ed9cb37a1198ba18c8942d14bb4256a460d2cfd4f9ffbaa84b4a84e3d77df},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42125229. Agents can read the archived copy with the MCP tool read_document.